ランキング価格はじめての方へ
  1. 米国企業
  2. IRONWOOD PHARMACEUTICALS INC

IRONWOOD PHARMACEUTICALS INCIRWD

時価総額
$7.1億
PER
サマリーテーブルに戻る
損益計算書バランスシートキャッシュフロー
2011年
12月31日		2012年
12月31日		2013年
12月31日		2014年
12月31日		2015年
12月31日		2016年
12月31日		2017年
12月31日		2018年
12月31日		2019年
12月31日		2020年
12月31日		2021年
12月31日		2022年
12月31日		2023年
12月31日
Net income (loss)-65-73-----117-28222106528175-1,032
Depreciation--------64212
Loss on disposal of property and equipment-0-0-1-000-12-0-0-0-0-
Share-based Compensation12182026252934443131222732
Fair Value Adjustment of Warrants----438-21-5816-12-11-1-0
Change in fair value of convertible note hedges----5-462467-1918121-
Non-cash interest expense--22815161820222422
Deferred income taxes-----------6673
Acquired in-process research and development------------1,095
Accounts receivable and related party accounts receivable, net-1224291017-169-4-8-8-
Accounts receivable, net-2------------1
Prepaid expenses and other current assets-2504-33-131-2-1-3-4
Inventory, net-7123---01--1---
Operating lease right-of-use assets---------14-1-1-1-1
Operating lease right-of-use assets---------14-1-1-1-1
Other assets-00-03-0-2-0-1-000-00
Other assets-00-03-0-2-0-1-000-00
Accounts payable and accrued expenses524-121-220-78-33-8-3-812
Accounts payable and accrued expenses524-121-220-78-33-8-3-812
Accrued research and development costs-1-1-201301-0-114-11-6
Accrued research and development costs-1-1-201301-0-114-11-6
Operating lease liabilities---------120-2-2-2
Operating lease liabilities---------120-2-2-2
Other liabilities---------1-1111
Deferred revenue--------1-1---
Other liabilities---------1-1111
Deferred income taxes-----------6673
Accounts receivable and related party accounts receivable, net-1224291017-169-4-8-8-
Accounts receivable, net-2------------1
Prepaid expenses and other current assets-2504-33-131-2-1-3-4
Inventory, net-7123---01--1---
Operating lease right-of-use assets---------14-1-1-1-1
Operating lease right-of-use assets---------14-1-1-1-1
Other assets-00-03-0-2-0-1-000-00
Other assets-00-03-0-2-0-1-000-00
Accounts payable and accrued expenses524-121-220-78-33-8-3-812
Accounts payable and accrued expenses524-121-220-78-33-8-3-812
Accrued research and development costs-1-1-201301-0-114-11-6
Accrued research and development costs-1-1-201301-0-114-11-6
Operating lease liabilities---------120-2-2-2
Operating lease liabilities---------120-2-2-2
Other liabilities---------1-1111
Deferred revenue--------1-1---
Other liabilities---------1-1111
Net cash provided by operating activities-75-70-273-156--25-100-7111169262274183
Purchases of property and equipment1014104444972000
Net cash used in investing activities11530-101-57--17815189-11-2-0-0-1,026
Acquisition of VectivBio Holding AG, net of cash acquired------------1,026
Net cash used in investing activities11530-101-57--17815189-11-2-0-0-1,026
Proceeds from Stock Options Exercised-----25263214192010-
Proceeds from exercise of stock options and employee stock purchase plan------------6
Repayment of 2022 Convertible Notes--------227--121-
Purchase of subsidiary shares from noncontrolling interests------------26
Repurchases of common stock----------24126-
Repayment of 2022 Convertible Notes--------227--121-
Net cash provided by (used in) financing activities389314211--42030-119-5-238277
Repurchases of common stock----------24126-
Proceeds from revolving credit facility------------400
Costs associated with revolving credit facility--8--00-----3
Repayments of revolving credit facility------------100
Net cash provided by (used in) financing activities389314211--42030-119-5-238277
Net increase (decrease) in cash, cash equivalents and restricted cash-------48-218625736-566
Effect of exchange rate changes on cash, cash equivalents and restricted cash-------------0
Net increase (decrease) in cash, cash equivalents and restricted cash-------48-218625736-566
Interest Paid, Net------20181877614
Income Taxes Paid, Net0--------23510
Stock repurchases payable in accrued expenses----------3--
Stock option exercise proceeds receivable in other current assets-----------2-
Interest Paid, Net------20181877614
Income Taxes Paid, Net0--------23510
Stock repurchases payable in accrued expenses----------3--
Stock option exercise proceeds receivable in other current assets-----------2-